MARKET WIRE NEWS

Spruce Biosciences to Participate in Upcoming Conferences in June

Source: Business Wire

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that members of the management team will present and participate in one-on-one meetings at upcoming conferences taking place in June.

  • Jefferies Global Healthcare Conference
    Date and Time: June 4, 2026, at 11:05 a.m. ET
    Format: Presentation and 1x1 meetings
    Location: New York

Interested parties can access the live webcast for the Jefferies Global Healthcare Conference on the events section of the Company’s website. An archived copy of the webcast will be available for approximately 90 days.

  • BIO International Convention
    Date: June 24-25
    Format: 1x1 meetings
    Location: San Diego, CA

1x1 requests can be made through the BIO Partnering™ system .

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. Spruce’s lead product candidate, tralesinidase alfa enzyme replacement therapy (TA-ERT), is in late-stage development for the treatment of mucopolysaccharidoses type IIIB (MPS IIIB), or Sanfilippo Syndrome Type B, a devastating pediatric neurodegenerative disorder for which there are no FDA-approved therapies. TA-ERT has received Breakthrough Therapy Designation, Rare Pediatric Disease Designation, Fast Track Designation and Orphan Drug Designation from the FDA, as well as Orphan Drug Designation in the European Union. To learn more, visit www.sprucebio.com and follow us on X , LinkedIn , Facebook and YouTube .

View source version on businesswire.com: https://www.businesswire.com/news/home/20260527638538/en/

Media
Carolyn Hawley
Inizio Evoke Comms
Carolyn.Hawley@inizioevoke.com
media@sprucebio.com

Investors
Monique Kosse
Gilmartin Group
Monique@GilmartinIR.com
investors@sprucebio.com

Spruce Biosciences Inc.

NASDAQ: SPRB

SPRB Trading

1.58% G/L:

$44.42 Last:

20,231 Volume:

$44.21 Open:

mwn-press-release-boost Ad 900
?>

SPRB Latest News

$90,018,117
658,278
2.53%
34
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco

Check Your Online Brokerage For SPRB

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App